文献速递肿瘤 PET/CT

健康志愿者与肿瘤患者的18F-(2S,4R)4-氟谷氨酰胺动态PET/CT显像

Dynamic PET/CT imaging of 18F-(2S, 4R)4-fluoroglutamine in healthy volunteers and oncological patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-03-12

本研究比较13名健康志愿者与31例癌症患者的18F-FGln与18F-FDG PET/CT图像,分析全身分布与肿瘤摄取。结果显示部分FGln阳性肿瘤不一定FDG阳性,反之亦然;乳腺与甲状腺癌SUVmax峰值在10分钟内,肺癌平台期在30至60分钟。作者认为18F-FGln显像可能补充18F-FDG的诊断能力,并需按肿瘤类型优化显像时间。

要点

  • 31例原发恶性病灶中29例在所有18F-FGln PET/CT显像期相均显示放射性摄取增高。
  • FGln阳性肿瘤不一定表现为FDG阳性,反之亦然。
  • 乳腺癌与甲状腺癌SUVmax峰值在10分钟内,肺癌SUVmax平台期在30至60分钟。

核心结论

  • 18F-FGln显像可能进一步补充18F-FDG在癌症患者中的诊断能力,并检测不同肿瘤的代谢变化。
  • 18F-FGln PET/CT的显像时间需针对不同癌症类型进行优化,以提高肿瘤对比分辨率。

研究设计与样本

  • 13名健康志愿者与31例癌症患者分别在1周内接受18F-FGln与18F-FDG PET/CT扫描。
  • 分析并比较18F-FGln与18F-FDG的全身分布及肿瘤亲和性。
  • 比较不同扫描期相18F-FGln PET的肿瘤SUVmax与肿瘤/非肿瘤SUV比值(SUR)。

主要发现

  • 与健康受试者相比,癌症患者在多数正常器官中18F-FGln活性(SUVmean)较低,尤其在肺、肌肉、脾和心脏(p < 0.05)。
  • FGln阳性肿瘤不一定表现为FDG阳性,反之亦然。
  • 31个经活检或术后病理分析确认的原发恶性病灶中,29个在所有18F-FGln PET/CT显像期相均显示放射性摄取增高。
  • 乳腺癌与甲状腺癌的SUVmax峰值在10分钟内,肺癌的SUVmax平台期在30分钟至60分钟。
  • 从早期到晚期采集,肺癌(p = 0.046)与甲状腺癌(p = 0.794)的SUR升高,而乳腺病灶的SUR显著降低(p = 0.022)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to compare dynamic 18F-FGln PET/CT images of healthy subjects and cancer patients and explore the best imaging phase for different cancers. METHODS: Thirteen healthy volunteers and 31 cancer patients separately underwent 18F-FGln and 18F-FDG PET/CT scans within 1 week. The distributions of 18F-FGln and 18F-FDG in the whole body and the tumor avidity were analyzed and compared. The tumor maximum standardized uptake values (SUVmax) and tumor-to-nontumor SUV ratio (SUR) of 18F-FGln/PET at different scan phases were compared. RESULTS: Compared to the healthy subjects, the cancer patients had lower 18F-FGln activity (SUVmean) in most normal organs, especially in the lung, muscle, spleen, and heart (p < 0.05). Additionally, the FGln-avid tumors did not necessarily manifest as FDG-avid and vice versa. Overall, among the 31 primary malignant lesions confirmed by biopsy or postoperative pathological analysis, 29 showed increased radioactive uptake on all 18F-FGln PET/CT imaging phases. The peak of SUVmax in breast and thyroid cancers was within 10 min, while in lung cancers, the plateau of SUVmax was within 30 min to 60 min. The SURs of lung cancer (p = 0.046) and thyroid cancer (p = 0.794) increased from the early-phase to the late-phase acquisition; however, a significant decrease was observed in the breast lesions (p = 0.022). CONCLUSIONS: 18F-FGln images may further supplement the diagnostic ability of 18F-FDG in cancer patients and detect metabolic changes in different tumors. Furthermore, the imaging time for 18F-FGln PET/CT needs to be optimized for different cancer types to improve the contrast resolution of tumors.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Xu X, Zhu H, Liu F, et al. Dynamic PET/CT imaging of 18F-(2S, 4R)4-fluoroglutamine in healthy volunteers and oncological patients. Eur J Nucl Med Mol Imaging. 2020. PMID: 32166510. doi:10.1007/s00259-019-04543-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。